25 Nov

AGM Presentation

Bluechiip Ltd. All Rights Reserved Annual General Meeting November 2021 Bluechiip Ltd. All Rights Reserved Material used in this presentation is a summary of available information, and while given in good faith, is professional opinion only. Any investor in Bluechiip Limited (BCT) should refer to all BCT ASX releases and statutory reports before considering investment in the company. Certain information may have been derived from third parties and though BCT has no reason to believe that it is not accurate, reliable or complete, it has not been independently audited or verified by BCT. Any forward-looking statements in this presentation involve subjective judgment and analysis and are subject to uncertainties, risks and contingencies, many of which are outside control of, and maybe unknown to, BCT. Neither BCT, nor its officers, employees and advisors make or give any representation, warranty or guarantee in relation to this presentation. BCT reserves right to update, amend or supplement information in this presentation at any time in its absolute discretion without incurring any obligation to do so. 2 Disclaimer Bluechiip Ltd. All Rights Reserved • World first, highly differentiated technology: 30 granted patents • Sophisticated markets: IVF, clinical trials, cell therapies, population biobanking and vaccines require Ultra Low temperature ID and temperature traceability • Over 300M/yr high value bio-samples preserved/transported at -80°C & -196°C • >$600M growing target market with large adjacent markets • Current ID methods are suboptimal both in productivity and quality • Capacity built for 5-10 million chips per year, 3m+ in stock • Major partnership: FujiFilm Industries Irvine Scientific for IVF market • Direct to market strategy: Bluechiip Enabled Solution Launched Q4 ‘21 • Cash in bank, $5m (end Sept), $1m due in R&D tax refund, zero debt 3 Bluechiip Fundamentals Drives productivity Redefines Quality Confidence in every sample Bluechiip Ltd. All Rights Reserved • FujiFilm Industries Irvine Scientific • Licence and development agreement for ART/IVF market • Bluechiip Enabled solutions launched • ISO9001, CFR21-11 software, CE IVD & FDA registration • Scaled chip supply chain (3m+) • International ISBER award: Bluechiip Cryobox Tracker • New market positioning, catalogue, collateral & Website • Labcon partnership resolved • $US850k cash received, $US750k product returned, Credit $US1.35m FY’21 – Key Achievements Sample Storage Readers Software Bluechiip Ltd. All Rights Reserved Bluechiip Enabled Solutions Launched Q4 CY2021 • Direct-to-market sales and support: US and ANZ • Distribution channels: EU, APAC and US • Initial orders & Installations in Oct and Nov ’21 • End Market Branding and Communication • New website www.bluechiip.com • Product Catalogue download here 5 Global Product Launch – Bluechiip Enabled Solutions Certifications Certified ISO9001 Quality Management System CE Marked Readers and CE-IVD Marked Consumables FDA Registered Products Bluechiip is a registered Australian Trusted Trader Sample Storage Readers Software Bluechiip Ltd. All Rights Reserved Bluechiip Overview 6 Link to corporate video https://www.bluechiip.com/investor/company-overview/ Bluechiip Ltd. All Rights Reserved Founded in 2003 | Listed on Australian Securities Exchange (ASX) 2011 | IP portfolio: 30 granted patents Head office in Melbourne, Australia | Direct Sales in North America and Aus/NZ | Global Distribution Partners Iain Kirkwood Chairman (Nov ‘07) Andrew McLellan Managing Director (Jan ‘15) Michael O’hanessian Non Exec Dir (Dec ‘14) Andrew Cox Non Exec Dir (July ‘17) Board Summary Number of Shareholders 1,678 (15.11.2021) Market Cap. AUD34.68m (15.11.2021) Share Price 5.8c (15.11.2021) Cash AUD4.89m (30.09.2021) Shares on Issue 597,880,502 (15.11.2021) Top Shareholders (as at 15 November 2021) HSBC Custody Nominees (Australia) Limited 12.75% JP Morgan Nominees Australia Pty Limited 5.46% Chairman & Entities 4.53% Top 20 Shareholders 46.03% Corporate Overview 0 20000000 40000000 60000000 80000000 100000000 120000000 0.0 1.0 2.0 3.0 4.0 5.0 6.0 7.0 21/05/21 21/06/21 21/07/21 21/08/21 21/09/21 21/10/21 Volume Price Weekly Share Price (cents) Volume Share Price (cents) Bluechiip Ltd. All Rights Reserved Vision To be the global leader in ID and sensing technology for extreme environments Mission To advance research and medicine by providing confidence in every sample 8 Bluechiip Ltd. All Rights Reserved 9 Major ID and Sensing Technology Sectors Lifesciences Cold Chain incl Logistics, Storage and Monitoring Cold Chain Logistics Food Industrial and Manufacturing Security and Defence Item level ID and temperature tracking of containers holding high value samples through-out the cryogenic cold chain cycle. Including Banking, Transport and Monitoring where frost is usually present, and ID errors have high risk and impact Item level tracking of frozen , and temperature sensitive food products through-out the cold chain cycle. Item level ID and high/low temperature tracking tools and parts, structural health monitoring, items exposed to ionizing radiation such as nuclear products, sterilised medical devices, disposables and some food products. Anti counterfeiting fashion, art, and high value commercial items. Cloning a bluechiip tag is extremely difficult. tracking of tools and parts that are exposed to ionizing radiation , security and defence. Bluechiip is highly differentiated in Lifescience Cold Chain with core technology benefits and large market opportunity Primary Focus Bluechiip Ltd. All Rights Reserved 10 Life-science Cold Chain Market Trends Increasing sample numbers and retrieval rates Increased demand for advanced therapies and sensitive samples Criticality of sample history maps and reports PRODUCTIVITY Minimise total cost of sample ownership and ROI SAMPLE VALUE ID tech needs to keep up with higher value samples SAMPLE QUALITY Maximise specimen integrity via adequate cold chain handling and reporting Increasing demand for cryo (-196 ° C and - 80 ° C) storage CRYO TECH Utilisation of cryo-safe technology and processes Bluechiip Ltd. All Rights Reserved 11 Biosample Management Technology is Not Keeping up With the Increasing Value of Biosamples Stem Cell Vaccines IVF Sperm/Eggs Blood Tissue Bluechiip Ltd. All Rights Reserved Global Bio-Preservation Market $3.1B in 2020 – Projected $4.9B in 2025 (CAGR 9.2%)^ 12 Primary Market Opportunity Samples in Storage* Total Bio-Preservation: 2B Samples in Storage 300M new samples per year Sources: Visual Fuse and Markets and Markets 2014 Primary Bluechiip Applications Life Science Market Opportunities Target Market Market Size by Samples Bluechiip Addressable Market Bio-preservation 300m+ samples/year >2B in storage US$600m+ Assisted Reproductive Technology (IVF) 2.5m IVF Cycles/year 5-8 consumables per cycle >33m samples in storage US$50m+ Clinical trials and research >35m samples/year US$70m+ Cell therapies, Pharmaceuticals 3m samples/year 15m+ in storage US$30-50m+ Sources: ^ Markets and Markets 2020 * Visual Fuse and MarketsandMarkets 2014 Bluechiip Ltd. All Rights Reserved 13 Bluechiip MEMS Core Technology Advantages Cryosafe Operates down to -196C Guaranteed unique ID ID cannot be overwritten or duplicated On-board sensor Senses temperature on each scan Sterilization proof Gamma, E-beam, Autoclave Barcodes Bluechiip Non-visual ID Reads through frost ? ? ? ? ? ? ? ? ? RFID ~ * ? ? ? ? ^ ? *Majority of RFID unreliable below -40C. ^Some newer RFID’s have resistance Bluechiip’s sensor tag consists of a silicon chip (1mm 2 ) with 52 mechanical beams that provide a unique ID when read. The chip is connected to an antenna available in multiple form factors, providing communication of both ID and temperature to a centralized database. Bluechiip’s Tag provides key advantages over other forms of ID in cryogenic conditions. Bluechiip Ltd. All Rights Reserved 14 Bluechiip offers the only Advanced Sample Management solution that provides sample temperature with ID in cryogenic environments We understand that every sample is critical and managing each one with optimal quality, in the most efficient way is the objective Bluechiip Enabled Storage Bluechiip Readers Bluechiip Stream Software Bluechiip’s goal is to deliver confidence in every sample Bluechiip Ltd. All Rights Reserved 15 Confidence in Every Sample Redefining Quality Capturing ID and temperature at the sample level for cold chain integrity Reducing the risk of temperature excursions in cryogenic conditions Providing key workflow insights to drive continuous improvement Eliminating errors through optimized inventory management Enabling compliance to industry standards and internal procedures Driving Productivity Reducing manual processes and eliminating double witnessing Identifying multiple samples instantly through frost Simplifying inventory handling for faster processing Driving efficiency at every step of the workflow Bluechiip’s unique and patented technology is designed to operate across a wide temperature range from -196°C to over +100°C, creating the perfect system for managing sensitive samples. Bluechiip Enabled Sample Storage, Readers and Software combine to provide an unparalleled ability to track and store sample level data, including temperature across the cold chain process. Bluechiip Ltd. All Rights Reserved 16 Bluechiips Path to Market Engagement (Non-Disclosure Agreement) (> 50) Sale of Developer/Trial Kit, Evaluation Agreement (35) Development and supply agreement (3) Demonstration in market (2) Commercial product “Bluechiip enabled” (1) • Developer kits sold to global corporations for due diligence • Conversion to licence agreements and Bluechiip Enabled solutions • Ongoing licence fees • Development and service revenues • Sale of Bluechiip Enabled Consumables, readers & software Bluechiip Direct Solutions • Direct to market: North America, ANZ and global distribution network • Consumables, Readers, Software Sales model Partnerships: Bluechiip Enabled Solutions Primary Target Markets • Bio-preservation • Clinical trials and research • Cell therapies & Pharmaceuticals • FujiFilm Industries Irvine Scientific • Licence and Development agreement • 18-24 month development project • Labcon distribution agreement Major Licence agreements Bluechiip Ltd. All Rights Reserved 17 Foundations Set • World first, highly differentiated technology: 30 granted patents • Sophisticated markets: IVF, clinical trials, cell therapies, population biobanking and vaccines require Ultra Low temperature ID and temperature traceability • >300M/yr high value bio-samples preserved & transported in -80°C/-196°C environments • >$600M growing target market with large adjacent markets • Current ID methods are suboptimal both in productivity and quality • Capacity built for 5-10 million chips per year, 3m+ in stock • Major partnership: FujiFilm Industries Irvine Scientific in IVF • Direct to market strategy: Bluechiip Enabled Solution Launched • Cash in bank, $5m end Sept, $1m R&D tax refund due, zero debt Bluechiip Ltd. All Rights Reserved Contact Andrew McLellan Managing Director & CEO Telephone +61 (0)3 9763 9763 Mobile +61 (0)457 823 470 Email andrew.mclellan@bluechiip.com bluechiip.com
Information on this Website is provided for general information purposes only and is not a substitute for professional advice. ASX Information (including company announcements and prices) is delayed by at least 20 minutes. JSE Information (including company announcements and prices) is delayed by at least 15 minutes. Reliance on the information you access on or from this Website is solely at your own risk. We make no representation or warranty in relation to the future performance of the companies that appear on this Website. Investment in securities involves risk and you should obtain independent professional legal, financial, investment or company advice before acting on any of the information you access on this Website. Using, browsing or otherwise accessing this Website is subject to our Terms and Conditions and our Privacy Policy.

© 2021 Listcorp. ABN 60 166 140 307

Never miss news from Bluechiip Limited (ASX:BCT) when you join Listcorp.